Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease

Publisher： Karger

E-ISSN： 1423-0194|105|1|90-104

ISSN： 0028-3835

Source： Neuroendocrinology, Vol.105, Iss.1, 2016-08, pp. : 90-104

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nuclear Survivin Is a Powerful Novel Prognostic Marker in Gastroenteropancreatic Neuroendocrine Tumor Disease

By  

Neuroendocrinology, Vol. 81, Iss. 1, 2005-05 ,pp. : 1-9

Karger

Access to resources Recommend Favorite

Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells

By  

Neuroendocrinology, Vol. 103, Iss. 6, 2015-12 ,pp. : 724-737

Karger

Access to resources Recommend Favorite

The Novel mTOR Inhibitor RAD001 (Everolimus) Induces Antiproliferative Effects in Human Pancreatic Neuroendocrine Tumor Cells

By  

Neuroendocrinology, Vol. 85, Iss. 1, 2007-02 ,pp. : 54-60

Karger

Access to resources Recommend Favorite

Therapeutic Monitoring of Gastroenteropancreatic Neuroendocrine Tumors: The Challenges Ahead

By  

Neuroendocrinology, Vol. 96, Iss. 4, 2012-10 ,pp. : 261-271

Karger

Access to resources Recommend Favorite

From Basic to Clinical Research in Gastroenteropancreatic Neuroendocrine Tumor Disease – The Clinician-Scientist Perspective

By  

Neuroendocrinology, Vol. 80, Iss. 1, 2004-10 ,pp. : 94-98

Karger

Access to resources Recommend Favorite